Qualified candidate Sample Clauses

Qualified candidate. A qualified candidate meets or exceeds the required job qualifications for the position, as specified in the job posting and position description (a.k.a. desk description), and determined by Human Resources to possess the skills, knowledge, and abilities for the position. Internal candidates who are determined to not qualify under this provision may request and will be provided a written explanation for their disqualification, including the specific qualifications and/or requirements the candidate did not meet.
Sample 1Sample 2Sample 3See All (16)
AutoNDA by SimpleDocs
Qualified candidate. In the event that two (2) or more employees, as determined qualified by the Company apply for the same position, the Company in making its decision will be governed by the factors in Article 13.01 (c) hereof.
Sample 1Sample 2
Qualified candidate. Qualified candidate is defined as any visitor to ------------------- XXxxxxxxx.xxx or XXxxxxx.xxx who clicks through to Leaders!Online.
Sample 1
Qualified candidate a. Public Works shall define qualified as having passed all hands-on testing stations with a cumulative score of seventy five percent (75%) or higher, when applicable. Management retains the right to evaluate candidates in an oral interview on a case-by-case basis to determine if the candidate is qualified for the position.
Sample 1
Qualified candidate. Has experience but lacks length or depth; experience may be with a small project with limited functionality. Participated in a closely supervised role rather than independent journey level. Worked on a portion of a project rather than involvement in all phases. Used software other than Intergraph, Arc/Info or ARCVIEW software. 1 point – Minimally Qualified Candidate: Meets the minimum qualifications of degree in MIS or BIS plus 1 year of experience but experience has been as a GIS user or in a support role rather than as a developer. For certain general KSAs, the same rating guidelines can be used in each question rating that KSA. The rating guidelines serve to focus the raters’ attention on the specific KSAs being assessed. For KSAs that are heavily weighted, it is suggested that more than one question be included in the T&E. The basis for scoring this type of examination is slightly different than that of the traditional T&E rmethod. Rather than evaluating past “exposures” that applicants have had in terms of work or education (e.g., work experience involving ), this method emphasizes past behaviors or achievements of the applicant. Since the focus is more on behaviors and achievements, and not broadly-defined experience or “exposures”, this method is better geared to evaluate the quality of what an applicant has done, achieved or accomplished (i.e., results achieved), than traditional T&E’s. The term “behavioral consistency” therefore stems from the idea that people tend to be consistent in their behaviors, and that future behaviors can be predicted by measuring past behaviors of a similar nature. This is not to say that individuals don’t change. They can. However, most of the important behaviors for most people do not change dramatically over reasonable periods of time. Again, because the Behavioral Consistency method is based on content validity, applicants are evaluated on only those behavioral dimensions that show large differences between superior and barely acceptable workers. Behaviorally anchored T&Es must be rated by more than one rater. The panel(s) of SMEs review the narrative descriptions provided by candidates and match them with the rating guideline’s set of detailed pre-established benchmarks, which exemplify performance at different levels of proficiency. Ideally, the different proficiency benchmarks associated with each task or function represent such markedly different levels of performance that they do not overlap. If there are highly...
Sample 1

Related to Qualified candidate

  • Combination Product The term “

  • Selection Criteria Each Contract is secured by a new or used Motorcycle. No Contract has a Contract Rate less than 1.00%. Each Contract amortizes the amount financed over an original term no greater than 84 months (excluding periods of deferral of first payment). Each Contract has a Principal Balance of at least $500.00 as of the Cutoff Date.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Board Composition Each Stockholder agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special meeting of stockholders at which an election of directors is held or pursuant to any written consent of the stockholders, the following persons shall be elected to the Board:

  • Joint Commercialization Committee The Parties shall establish a joint commercialization committee (the “Joint Commercialization Committee” or “JCC”) at an appropriate time, reasonably in advance of the first potential Marketing Approval of a CoDev Product and reasonably in advance of the time required for the Global Commercialization Strategy to be prepared as set forth in Section 6.1.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Time is Money Join Law Insider Premium to draft better contracts faster.